Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Founded in 2015, Tempus has built one of the world's largest libraries of clinical and molecular data, along with an operating system to make that data accessible and useful. The company's mission is to empower healthcare professionals and researchers with cutting-edge tools and insights, enabling them to make data-driven decisions for personalized patient care. Tempus provides genomic sequencing services and analyzes molecular and therapeutic data to help physicians make real-time, data-driven decisions. Their platform integrates and analyzes vast amounts of genomic, transcriptomic, and clinical data to improve health outcomes and accelerate discovery in life sciences. The company's work extends across multiple disease areas, with a particular focus on oncology, neurology, cardiology, and infectious diseases. Tempus offers services for clinical trial design and patient matching, as well as tools for real-world evidence generation. They have developed AI-enabled diagnostics and personalized medicine solutions, and their platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions. Tempus claims to be connected in some way to more than 50% of all oncologists practicing in the United States. The company has raised over $1.3 billion in funding and has expanded its capabilities through strategic acquisitions. Tempus generates revenue through various segments, including genomic sequencing, data licensing, and clinical trial services. While the company has achieved significant scale in terms of revenue, it is not yet profitable. Tempus continues to innovate in areas such as digital pathology, voice-activated clinical assistants, and institutional data sharing platforms.